Anastrozole vs MENT
FDA Approved vs Emerging
compatible Researched · 90% Aromatase inhibitors have reduced efficacy with MENT because its aromatization product, 7-alpha-methyl-estradiol, is a methylated estrogen that is less effectively blocked by conventional AIs. Anastrozole will still provide some estrogen control but typically not as complete as when managing estrogen from testosterone. Users may need higher AI doses than expected, and some find AIs insufficient at higher MENT doses. Monitor symptoms and bloodwork closely -- standard estradiol assays may not fully capture 7-alpha-methyl-estradiol levels.
Molecular Data
Anastrozole MENT
Weight 293.37 Da 288.43 Da
Half-life ~40-50 hours ~40 minutes (acetate ester)
Type Nonsteroidal aromatase inhibitor (triazole derivative) 7-alpha-methyl-19-nortestosterone (C19H28O2)
Key Benefits
Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
MENT
01 Approximately 10x more potent than testosterone, allowing effective results at very low doses (5-25 mg/day)
02 Does not cause the sexual dysfunction associated with other 19-nor compounds like nandrolone
03 Can potentially serve as a standalone base, replacing testosterone in hormone replacement protocols
04 Rapid clearance of the acetate ester allows quick dose adjustments and fast resolution of side effects upon discontinuation
05 Powerful lean mass accretion and strength gains relative to dose
06 Under investigation as a reversible male hormonal contraceptive
07 Resistance to 5-alpha reductase means it does not convert to DHT, potentially sparing hair follicles from direct DHT-mediated damage
08 Robust suppression of gonadotropins (LH/FSH), which is therapeutically useful in contraceptive applications
Dosing Protocols
Anastrozole
0.25-0.5mg EOD or E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
MENT
5-25 mg/day (acetate) / Daily or split into 2x daily (acetate ester)
TRT Replacement - Low Dose 5-10 mg/day Daily (or split into 2 injections per day)
Moderate Anabolic Protocol 10-15 mg/day Split into 2 injections per day
Higher Dose - Advanced 15-25 mg/day Split into 2 injections per day
Side Effects
Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
MENT
Estrogen management difficulty -- 7-alpha-methyl-estradiol is harder to control with conventional aromatase inhibitors
Water retention and bloating, particularly at doses above 10 mg/day
Elevated blood pressure, often linked to water retention and estrogenic load
Mood changes including irritability, emotional sensitivity, or anxiety (frequently estrogen-related)
Profoundly suppressive of the HPG axis -- LH and FSH driven to near-zero even at low doses
Injection frequency burden (daily or twice-daily with acetate ester)
Mild acne and oily skin
Increased appetite
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy
Severe hepatic impairment
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled hypertension or severe cardiovascular disease
Uncontrolled heart failure
Known hypersensitivity to trestolone or any formulation components
Research Evidence
Anastrozole MENT
Status FDA Approved Emerging
References 5 studies 5 studies
Latest — 2002
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.